Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double Dose Tenecteplase in Acute Ischemic Stroke
NCT06801054Phase 1Not yet recruiting
- Sponsor
- Memorial Hermann
- Start
- Jul 2025
- Primary completion
- Jun 2026
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tenecteplase in ischemic stroke, sponsored by Memorial Hermann. Primary endpoint: Symptomatic Intracerebral Hemorrhage or Major Systemic Bleeding at 36 hours. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06801054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06801054.